While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance. Investors looking beyond large-cap names may find compelling opportunities in mid-cap stocks that deliver strong growth and defy broader market weakness.
Here are three mid-cap medical stocks that have significantly outperformed the broader market so far this year. Each shows strong momentum, bullish analyst sentiment, and potential for continued upside.
Penumbra: A High-Growth Medical Devices Company Outperforming the Market
[content-module:CompanyOverview|NYSE: PEN]Penumbra, Inc. (NYSE: PEN) designs, develops, manufactures, and markets innovative medical devices used in neuro and vascular interventions. With a market capitalization of $11.3 billion, the company has emerged as a standout performer in the medical device space. While recession concerns and geopolitical uncertainty have weighed on equities broadly, Penumbra’s stock is up an impressive 23% year-to-date and 43% over the past 12 months.
The company reported strong first-quarter earnings on April 23, posting earnings per share of $0.83, beating consensus estimates by $0.17. Revenue climbed 16.3% year-over-year to $324.1 million, exceeding expectations of $315.7 million. Despite market volatility in April, Penumbra held its uptrend and trades just 5% below its 52-week high, indicating continued investor confidence.
Valuation remains elevated, with a trailing P/E ratio of 274, though its forward P/E of 58 better reflects its growth trajectory. Analysts remain bullish. Of the 17 analysts covering the stock, the consensus rating is a Moderate Buy, with a price target that points to further potential upside.
TransMedics Group: Momentum and Growth in Organ Transplant Technology
[content-module:CompanyOverview|NASDAQ: TMDX]TransMedics Group (NASDAQ: TMDX) is a commercial-stage medical technology company revolutionizing organ transplant procedures. The firm’s flagship product, the Organ Care System (OCS), preserves donor organs in near-physiological conditions, significantly extending the window for transplantation. The company also offers the National OCS Program, a turnkey solution for organ retrieval and logistics.
The stock began to rally in April after breaking out above key resistance around $80. Since then, shares have gained substantial momentum and are now up nearly 48% year-to-date. The stock’s high P/E ratio of 91 may give some investors pause, but its forward P/E of 41 suggests strong earnings growth ahead.
Analysts are optimistic about the company’s outlook. Eleven analysts cover the stock, all contributing to a Moderate Buy consensus rating. The consensus price target implies up to 35% upside from current levels.
One catalyst and factor contributing to the stock's surge and momentum is its high short interest. As of April 15, short interest stood at 28% of the float, about 8.8 million shares. While down 7.3% from the prior month, the elevated level may contribute to a short squeeze dynamic, fueling the rally.
ADMA Biologics: Biotech Strength With Room to Run
[content-module:CompanyOverview|NASDAQ: ADMA]ADMA Biologics (NASDAQ: ADMA) is a biopharmaceutical company that develops, manufactures, and markets plasma-derived biologics for treating immune deficiencies and infectious diseases. With a market cap of $5.6 billion, it’s one of the most impressive biotech performers of 2025, with shares up 38% year-to-date.
The stock is trading just 7% below its all-time high, which was reached in late April. Investors will be watching closely as the company is scheduled to report earnings on May 7. ADMA trades at a P/E of 29 and a forward P/E of 23, supported by projected EPS growth of 45% in 2025.
Despite limited analyst coverage, only four analysts cover the stock, all of them rate it as a Buy, reinforcing the stock’s strong growth profile and favorable risk-reward balance.
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
